(as of 6/19/2021)
Founded in 2008, AdOM is a clinical development and commercial stage ophthalmic device company which developed a non invasiv4, 40 second, proprietary imaging device (Tear Film Imager – TFI). This device is designed to measure the muco-aqueous and lipid sublayers simultaneously and is the first device to do so at a depth resolution of a few nanometers. The TFI has the potential to address all diagnostic parameters associated with the diagnosis and treatment of ocular surface diseases such as Dry Eye Disease.
Aesyra is a game changer in the treatment of bruxism, thanks to a smart oral appliance that replaces traditional dental splints, which are ineffective to treat this condition. After having CE marked the first bruxism monitoring device (AesyBite Discover), the company is now conducting clinical trials on a bruxism treatment device (AesyBite Active) with the aim of launching this disruptive solution on the market in 2022 and improve the quality of sleep of millions of people.
Through our wearable device, the Alio SmartPatch, we are able to track vitals like temperature, oxygen saturation, blood pressure and more. Whether you’re at home, in the clinic, out on the ice rink, or up in the sky, our continuous sensing technology will capture actionable metrics and create alerts. Performance, even as a clinician or an athlete, relies upon accurate data.
AMRA is a ground-breaking, international digital health company at the forefront of medical imaging and precision medicine. The company has developed a new global standard in body composition assessment, the ability to automatically produce multiple fat and muscle biomarkers with unrivaled precision and accuracy, alongside contextual disease insights – all from a single, rapid, whole-body MRI. AMRA was founded in 2010 as a spin-off of Linköping University, Sweden, with the aim to support transformative care and vital decision-making, from clinical research to health and wellness.
Biohope is a commercial stage biomedical company focused in the R&D of PRECISION MEDICINE IVD tools, to improve clinical outcomes in patients with chronic inflammatory conditions and autoimmune diseases. Biohope has developed an IVD kit called Immunobiogram® to facilitate a personalized drug treatment for patients with chronic inflammatory diseases.
We specialize in the creation of AI-powered imaging biomarkers to enable precision medicine for better treatment decisions. Since launching as a spin-out from the University of Oxford in 2012, we have developed award-winning, AI-powered imaging biomarkers and software solutions, assisting physicians across the world to make better life-saving decisions. Our e-Stroke is a CE-marked collection of tools that use our state-of-the-art AI algorithms to support doctors by providing real-time interpretation of brain scans to help guide treatment and transfer decisions for stroke patients, allowing more patients to get the right treatment, in the right place, at the right time. Our e-Stroke Mobile app, supported by the e-Stroke Cloud, is a tool enabling physicians across a network to have quick, easy access to critical results – including pseudonymized scan results – strengthening the connection between clinicians, and facilitating faster treatment decisions.
BBM has developed a simple, accurate and non invasive breath test to detect lung cancer and other diseases early. We have significant proof of concept data and an extensive IP portfolio. We are the only company that makes use of CRDS for disease detection.
Cognito Therapeutics is a clinical-stage company developing a pipeline of disease-modifying digital therapeutics that have clinically demonstrated drug-like effects using gamma frequency neuromodulation to treat neurodegenerative disorders including Alzheimer’s disease. The company’s licensed proprietary gamma frequency neuromodulation platform technology, developed by scientific founders at MIT, Professors Li-Huei Tsai and Ed Boyden is a non-invasive therapy utilizing visual and auditory stimulation to treat neurodegenerative diseases.
Founded by industry veterans, Efemoral Medical, Inc. is a clinical stage company developing a next-generation bioresorbable drug-eluting scaffold to treat peripheral arterial disease (PAD). PAD is a global plague that afflicts over 200 million people. Left untreated, it can lead to debilitating leg pain, open leg/foot wounds, and gangrene. Current treatment options are either ineffective or highly invasive. The Efemoral Vascular Scaffold System is designed to be an easy-to-use workhorse solution that provides high radial strength, accommodates the complex skeletal motion in the leg, elutes drug to prevent restenosis and is naturally absorbed by the body so that no permanent implant is left behind.
Founded in 2016 in Oakland, Calif., Elemeno Health is a digital health start-up backed by leading seed stage digital health investor, Launchpad Digital Health, Silicon Valley tech accelerator, Y Combinator, and leading regulatory tech venture investor, Fenway Summer. Developed in collaboration with UCSF, the company’s app engages frontline nurses, doctors and ancillary staff to help them adhere to the consistent delivery of best practices while enhancing teamwork. The Elemeno Health platform is designed as a cloud solution accessible from any device – from desktop to mobile. Elemeno Health is a 2016 Medical Entrepreneurship & Disruption (MEDy) award winner, and its app is in use by teams in multiple large academic medical centers, county health systems and provider practices.
EndoShape, Inc. (Boulder, Co USA), an expert in radiopaque shape memory biocompatible polymers, develops polymer based, minimally invasive embolization and occlusion devices for peripheral and neurovascular applications in the interventional radiology market that will substantially replace existing technology. Current embolization coils are made of metal which cause large artifacts reducing the quality of CT and MRI imaging. EndoShape’s polymer based coils cause virtually no artifacts. EndoShape’s 510(k) is currently under review with the FDA and already knows that its coil technology is superior to the predicate device in all aspects.
Entac Medical is developing medical devices for predictive and diagnostic medicine based on a new platform technology, audio spectral analysis. Its first application, PrevisEA, is a late stage, Class II noninvasive, disposable device that is clinically proven to predict post-operative ileus (POI) in surgical patients (GI paralysis occurs 2-6 days after surgery in 25% of patients). Prediction of ileus risk improves treatment protocols and patient outcomes while reducing readmissions and saving hospitals millions of dollars in unnecessary treatment costs.
Eyedaptic, is a software technology company addressing the large unmet need in the ophthalmic field of AMD (Age Related Macular Degeneration). Our visually assistive solutions are based on open market Augmented Reality (AR) glasses and embeds our proprietary simulated natural vision software, which optimizes the person’s functional peripheral vision to help restore the entire scene for the wearer. Eyedaptic’s software is adaptive to the user’s particular vision limitation, as well as their environment and habits with machine learning and optimizes their field of view. The camera views the surroundings, manipulates the pixels and re- displays the image, with an adapted visual field for the wearer thereby effectively addressing central vision loss.
Edge AI at the point of care, Hoana Medical initially focused on acute-care hospital medical-surgical ward patients with the FDA approved LifeBed™, providing “Intelligent Medical Vigilance” that invisibly tracks patient vital signs without any connections whatsoever, intelligently calling for assistance when the patient is in distress. Used by over 100,000 patients in 34 acute-care hospitals, providing over 10 million hours of continuous use, the LifeBed has delivered 4,000 life-changing interventions. Hoana’s edge AI technology – observes, analyzes, notifies and reports with a very simple, inexpensive and scalable patient safety solution that not only is suitable for acute-care hospitals, but great for nursing centers and home environments.
We are developing a new technology for diagnosing and treating cancer, Covid 19, and other diseases using holography. The technology is called Holographic Energy Teleportation (HET) and the treatment is called Holothermia TM. It uses our advanced nanoparticles (AdvaNanTM) to target pathogens and diseased cells. We are using this new technology to develop a new type of theranostic MRI system with no gradient switching, thus providing noiseless, real-time (video) 3-D scanning of the entire body simultaneously with cellular resolution, as well as a portable system without a magnet. When disease is found, it can be treated at the same time.
i-Lumen Scientific, Inc. is an Ophthalmology company that developed a novel palpebral neurostimulation treatment for Dry Age-related Macular Degeneration (Dry-AMD). AMD is the leading cause of blindness in those over age 60 and affects 110 million globally with no available treatments. i-Lumen's office-based therapeutic delivers stimulation to the Retinal cells to slow the progression of Geographic Atrophy and help restore visual acuity. In an Open Label Study, more than 69% of eyes treated demonstrated an improvement in Visual Acuity of more than 10 letters (FDA requires a minimum improvement of 10 letters) as measured using the ETDRS chart. i-Lumen’s clinical and regulatory pathway is clearly defined, and the commercialization strategy is focused on partnering with an Ophthalmology-based strategic to establish this physician-delivered procedure.
Immunicom, Inc. is a privately-held medical technology company located in San Diego, California and Houston, Texas, focused on developing innovative, non-pharmaceutical approaches for treating cancer, inflammatory diseases, and autoimmune diseases. Immunicom’s revolutionary blood-filtering technology has the potential to effectively treat a wide variety of cancer types, including those that have not responded to other treatment strategies, including other drug and biological-based immunotherapy options, with possibly fewer side effects. The company seeks to leverage its technology to address unmet medical needs and improve patient access and affordability of cancer and other inflammatory and autoimmune disease treatments around the world.
Implandata is a transformational ophthalmic digital health/device company based in German and the US. We will improve the life of millions glaucoma patients by introducing remote disease management. Our CE marked EYEMATE system is ready for commercial launch in Europe and Breakthrough Device Designation ensures an expedited FDA market authorization process and Medicare reimbursement. We are currently raising our last funding round prior an exit.
We provide specialized telehealth services under contract to hospitals (no third-party billing) using our proprietary software and other systems. We specialize in Intensivist and critical care services for the ICU and related areas. Our service saves lives and generates significant ROI for our clients.
Breast cancer touch 1 in 8 women in the world, in 40% of cases, mastectomy is the usual treatment followed by chemotherapy or radiotherapy. Only 14% of women receive reconstructive surgery due to lack of reconstruction procedures. LATTICE MEDICAL develops MATTISSE, a fully degradable 3D printed hollow breast implant allowing a natural breast reconstruction in a single and simple surgery. MATTISSE technology uses a Tissue Engineering Chamber (TEC) implanted in the former breast and made of 3D printed biocompatible and bioabsorbable polymer. MATTISSE regenerate autologous adipose tissue from three to six months and fully degrade after eighteen months. Woman has recovered a full breast in a year and half, and implant has disappeared. No more risk like long term silicone implant, full recovery with natural tissues.
LifeBridge is a preclinical, wearable therapeutic device company dedicated to extending the proven benefits of Tumor Treating Fields (TTF) therapy to patients with metastatic cancer using our ADAPTIVE Tumor Treating Field (ATTF) technology. ATTF is patented in 7 countries, including two (and counting) U.S. issued patents. Our Mission is to transform metastatic cancer from a terminal prognosis to a manageable chronic disease like diabetes. We have approved Animal and Human Pilot trial protocols from the FDA and we have already received a term-sheet to purchase the company by a major MedTech company. Our team and investors unanimously concluded that we should not sell now given the huge value creation ahead of LifeBridge in the next 24-30 months.
Lindis Blood Care is a medical technology company aiming to set the new gold standard in oncological blood management to enable autologous blood transfusion in oncological surgeries. To reach this goal, LBC is combining currently used filter technologies with its trifunctional antibody to reliably remove EpCAM-positive cancer cells from intraoperative blood with its medical device CATUVAB ® . So CATUVAB ® has the potential to eliminate the negative side effects associated with allogeneic blood transfusions.
Immuno-oncology has been a paradigm shift in cancer treatment with close to $ 20B R&D investments only in 2020, growing >10x over last decade. Such R&D requires tremendous amount of data to be extracted from each tumour to understand how the immune system is fighting against cancer in a spatial location map context. The next big thing in life-science tools will therefore be spatial and Lunaphore is uniquely positioned to capture this opportunity in a large scale. Unlike others that are application specific probe or application innovations, Lunaphore brings a full-stack & application agnostic approach to enable mainstream access to spatial biology. We’re unlocking the vast market with simple, fast, affordable and precise solutions enabled by our unique technology.
LynxCare's proprietary technology uses AI-powered big data platform to aggregate both clinical and patient-reported data points and provides custom tools and API's to both statistical interfaces and clinical pathway from the various siloed data sources, enabling healthcare practitioners to improve the outcomes of their procedures and provide tailored care to their patients in real-time.
Founded by St. Jude Medical Founder Manny Villafana, Medical 21 is a developer of an artificial graft designed to use in coronary bypass heart surgeries. The company s products include an artificial blood vessel as an alternative to harvesting blood vessels for coronary artery bypass surgeries, enabling cardio surgeons to make cardiac bypass surgery easier for patients and less expensive for the healthcare system.
Med-Storm Innovation faces the challenges of pain management by offering a unique PainSensor for precise measurement of real-time pain assessment. The PainSensor measures pure changes in skin conductance, and is therefore not influenced by hemodynamic and respiratory instability. The technology can be used to tailor the need for analgesia and sedatives, to reduce side effects from over- and under sedation, as well as reducing the length of stay and costs for the hospitals. The PainSensor has various features and application areas for the hospitals and for home-treatment of patients (e.g. intensive care and palliative care). Med-Storm Innovation is further developing other telemedicine, data storage and cloud-solutions, constantly aiming to improve patient care and caregiver satisfaction.
Modality.AI measures speech, facial, and behavioral patterns indicative of the status of neurological and psychiatric conditions. We streamline assessments through computer vision and audio analysis to deliver objective measurements. Specific protocols include ALS, Parkinson’s, autism, stroke, schizophrenia, and depression. Modality was founded by world-class AI/ML experts with over 200 publications and issued patents and led by a team with several successful exits.
MY01 is a state-of-the-art medical device geared towards aiding in the detection of Compartment Syndrome (ACS); a limb-threatening muscle condition which occurs within 48 hours following a trauma. Currently ACS is diagnosed based on subjective and unreliable outcomes like pain (known as 6 P’s), which when present cannot confirm the diagnosis in time for effective intervention. This leads to increased complications (muscle necrosis/amputation) and costs the US healthcare system more than $2.25 B annually. MY01 is capitalizing on a proven correlation between sustained increase in Intramuscular pressures and ACS for objective, early diagnosis. MY01 operationalizes muscular pressure monitoring into a simple, accurate single-use device. MY01. The simple solution to a dangerous problem.
Nano4Imaging GmbH (N4I) was founded in January 2011 and now based in Dusseldorf (Germany). Our company vision is to enable minimal invasive procedures for MRI, and to do this we produce and market MRI compatible instruments both under FDA and CE label, and markers that allow guidance and visibility of other medical devices. N4I has an extensive network of clinical users in congenital heart disease, pulmonary hypertension and is gradually entering interventional radiology procedures such as angioplasty and SIRT. N4I’s know-how and IP concerns nanoparticles of different size, coatings, and magnetic susceptibility to enable visibility of instruments in MRI, MPI and CT under the product name MagnaFy. N4I has a CE and FDA certified guide wire for use in MRI under the tradename EmeryGlide. In addition N4I is now exploring the use of artificial intelligence to detect and localize its marker technology, in communication with existing MRI platforms.
NanoView Biosciencesenables life science researchers to better understand the biological role of exosomes and viral vectors and their potential use as biomarkers for improving the diagnosis, prognosis, treatment, and monitoring of disease. The company’s proprietary product, the ExoView® platform, is designed to specifically detect and fully characterize exosomes and viral vectors for use in basic and translational research, enabling the development of diagnostic and therapeutic products for nanomedicine.
Nephria Bio, Inc. is a US-based medical technology start-up developing next-generation dialysis solutions including an advanced dialyzer (cartridge) that may significantly reduce the hemodialysis treatment time, and an ambulatory hemodialysis (HD) or peritoneal dialysis (PD) which may alleviate the burden of visiting dialysis centers and improve the quality of life for dialysis patients. Contact:
nRichDX is an emerging leader in the liquid biopsy sample prep market. The company's Revolution Sample Prep System is a preanalytical platform that delivers much higher amounts of rare target analytes such as ctDNA, CTCs, and exosomes as compared to other sample prep methods. Revolution is the only IVD-labeled sample prep method capable of up to 20mL of blood plasma, or urine in a single extraction. Revolution sample prep works with many downstream analysis methods such as Next Generation Sequencing (NGS) and ddPCR, enabling broad applicability in the rapidly growing multi-billion dollar liquid biopsy market.
OtoNexus is developing the world’s first medical device to provide objective diagnostic data to instantly and accurately diagnose middle ear infections (Otitis Media) in children and adults. A simple and elegant solution, the device applies a well-known medical technology, ultrasound, in a completely novel way to achieve a key advance in differentiating when and when not to prescribe antibiotics. One-use-per-patient tips create a recurring revenue stream. The device will provide data in seconds and will be easy to use by physicians or non-physician personnel (NPs, PAs). Definitive, objective data identifying both the presence and the type of fluid behind the eardrum will lead to better outcomes and significantly reduced healthcare costs.
Pedra Technology's Xauron Perfusion System is a FDA-designated Breakthrough device for real-time perfusion monitoring in the angio suite during peripheral interventions for treatment of CLTI. Used in conjunction with angiography, we guide physicians to achieve adequate restoration of microvascular blood flow to ischemic feet. We are past FIH clinicals, and are raising a US$15M Series B to drive regulatory approval and further clinical studies.
Preventric is a commercial-stage digital health company redefining the way vascular diseases are clinically diagnosed by combining wearable biosensing technology with cloud-based data analytics and machine learning capabilities. The company derives its revenue in the United States. Its BPro® wearable has been in 20+ clinical trials on 20,000 patients, cited in 70+ peer-reviewed science & medical journals, globally patented, and FDA-cleared for physician use and reimbursement.
Provisio Medical is working to revolutionize endovascular procedures through the development of Sonic Lumen Tomography (SLT™), a novel intravascular ultrasound technology that provides accurate and precise real-time flow lumen dimensions. The SLT platform may also be easily integrated into many of the endovascular devices that physicians are already using today. Without the shortcomings of the low-resolution angiography’s ionizing radiation and kidney-toxic contrast media, Provisio’s SLT platform looks to seamlessly provide physicians the exact information they need, when they need it, to improve both clinical workflows and outcomes.
Qidni Labs, Inc., is a venture capital backed medical device company disrupting the $60B/year dialysis market by developing advanced blood purification and dialysis technologies for millions of patients with kidney failure around the world. Qidni Labs is aiming to be an independent dialysis provider without owning any dialysis clinics. The company is achieving that goal through the development of miniature, waterless dialysis machines which are managed and monitored by a cloud-based remote monitoring system. Currently, one session of dialysis requires 500 cups of highly purified water. We have reduced that volume to about a cup only. The technology has been validated for daily dialysis in a long term study in sheep with kidney failure and the company is preparing for its pilot clinical studies in humans.
Transverse Medical Inc. (TMI) is developing the POINT-GUARD™ Dynamic Cerebral Embolic Protection (CEP) medical device to address the devastating and costly problem of stroke during the large and growing number of heart valve procedures that occur annually around the world, such as Transcatheter Aortic Valve Replacement (TAVR). POINT-GUARD™ is a highly differentiated and proprietary medical device designed to more effectively provide maximum filter coverage to protect the brain, minimize embolic particles from the cerebral flow, and minimize the risk of stroke.
Renalis is creating a suite of prescribed digital therapeutics (PDT) designed for patients with pelvic health disorders such as overactive bladder (OAB), fecal incontinence, fibroids, endometriosis or chronic pelvic pain. The company’s first go-to-market platform for fibroids/endo will be available 3Q20, followed by another for OAB, for which the company anticipates seeking FDA approval in 2021 following clinical trials. Renalis is based in Chicago at MATTER, but serves a global market.
Retriever Medical, a private medical device company, seeks to transform the interventional approach to venous clot extraction with their proprietary SentryDuo™ Mechanical Thrombectomy Aspiration System, allowing physicians to treat both Pulmonary Embolism (PE) and Deep Vein Thrombosis (DVT) without the need for thrombolytics and extensive ICU stay. SentryDuo is the only mechanical thrombectomy system that provides a single design for PE and DVT procedures. Further, it is the only mechanical thrombectomy system to provide active expansion of two independently moveable spheres to mobilize, capture, disrupt and extract venous clot, offering controlled wall-to-wall vessel contact in a single session. The proximal sphere design allows physicians to mobilize clot by axially moving 6 cm along the device shaft in an antero and retrograde direction to safely perform luminal wall curettage.
SaiOx, Inc. has developed a patented breathing device that utilizes the proven benefits of heliox in a novel system to provide relief to patients with respiratory diseases, such as chronic obstructive pulmonary disorder (COPD). The low density heliox used in the system carries oxygen more easily and deeper into the lungs, decreasing the work of breathing and increasing patient blood oxygen levels. Additionally, the low pressure of the system decreases patient breathing discomfort, therefore increasing treatment adherence because patients are more inclined to continue its use. In comparison to current technology, SaiOx’s breathing device more quickly and less expensively treats COPD and other respiratory diseases through reducing ICU stays and consuming less O2 and HeO2 gas over time.
Solenic Medical, Inc. is a medical device company developing an innovative non-invasive treatment for infected metallic implants in the body. Using technology invented at the University of Texas Southwestern, Solenic is leveraging the unique properties of alternating magnetic fields (AMF) generated by external coils to eradicate biofilm on the surface of medical implants. This non-invasive treatment addresses a major complication of various surgeries such as knee and hip replacements, as well as in trauma related implants such as plates and rods. This is particularly important given an aging population and the rapid increase in the number of these procedures being performed every year.
Per 2021, Syntellix is the only company in the world with product registrations for a bio-absorbable metallic implant for orthopaedic and trauma use in Europe as well as many global top-notch product registration regimes on all five continents. Recently, Syntellix has been honoured as 2020 European Entrepreneurial Company of the Year in its industry by the internationally leading market research firm Frost & Sullivan, and its key implant even received Breakthrough Device Designation by the U.S. FDA. The company has developed a globally unique patent-protected magnesium-based technology platform called MAGNEZIX®, which is potentially suited to replace and disrupt most of the existing titanium-, steel- and polymer-based technologies as well as many other markets in medicine and beyond. Innovative implants based on the MAGNEZIX® technology platform have been approved for 67 countries around the world. The company already offers 6 product lines with 184 product derivatives, and has two headquarters in Germany and Singapore, as well as subsidiaries in / for key markets / countries like the US, China and India. Clinical evidence, product efficacy and even superiority, as well as Key Opinion Leader (KOL) acceptance have been shown and proven in total in 40 scientific publications in international peer-reviewed scientific journals and through tens of thousands of MAGNEZIX® devices which have already been implanted successfully and with extraordinarily high patient satisfaction.
Thrive Bioscience, located in the Boston area, offers customers a family of instruments and software that provide imaging, analytics, and automation for reproducible adherent cell culture. Our products empower biologists by combining advanced software, microscopy, and robotics, to acquire, organize, and analyze images of all their cells.
Varigen Biosciences is a synthetic biology company focused on manufacturing and creating high-value therapeutic drugs for humans and animals and biocontrol agents for plants. Our vision and goal are to transform the production and discovery of microbial small molecule drugs with genome-enabled technologies that are significantly faster, more effective, more affordable, and more universally applicable across major markets than those currently available.
VeoSource is an innovative Swiss medical company with the mission to change the path of stroke. Stroke is a devastating disease killing and disabeliting millions of people per year. Our first product aims to protect against strokes, patients who are undergoing minimally invasive aortic valve replacement, commonly known as TAVR, which is to become the number one cardiac intervention in the future. Our product is a temporary, embolic protection device for use during and immediately following TAVR to prevent embolic material from traveling towards the cerebral circulation. It is the only embolic protection device to protect patients during and beyond TAVR, when most of stroke events occur.
ViaTechMD has invented and developed the first and only device-based treatment specifically designed to treat a wide range of conditions known to contribute to preterm birth, which takes the lives of over 3,000 babies each day. The Company’s globally patented device, the Cervical Stabilization Device, has undergone successful human fitment studies and promises a highly accessible, cost-effective, non-invasive, and medication-free, treatment within a Year-5 total addressable market that exceeds $240B. ViaTechMD’s world-class management and advisory team has more than 130 years combined experience in the healthcare and medical device industries, including a $400MM exit.
ZKR Orthopedics is developing a novel 30 minute outpatient procedure incorporating a family of knee implants to be placed on the proximal tibia, below the patellar tendon. The procedure is intended to offload the patellofemoral joint and reduce pain for the millions of people who suffer from chronic knee pain caused by Patellofemoral cartilage degeneration. These patients have failed conservative therapy, but are not yet willing to undergo complex surgery - Total or partial knee replacement or tibial tubercle osteotomies. No comparable therapy exists for $1B+ addressable market.
Zumlase/CosmoAesthetics (“CA”) is an Australian based innovation hub focused on emerging disruptive technologies for use by global consumers in the provision of home-based health care products and services. CA has a team of Scientists and Physicians expanding the use of Low-Level Light Therapy (“LLLT”) in advanced medicine. This team has partnered with a group of experienced commercial professionals to bring these technologies to the market. LLLT and other energy-based technologies developed by CA, provide targeted options in the aesthetic and therapeutic markets. As a winner of the 2019 FTZ Overseas Most Talented Innovation Company, CA is a resident of the Johnson & Johnson JLABS facility in Shanghai. Servicing the greater Asia Pacific region, this state-of-the-art facility gives CA access to resources in research, development, and production in healthcare driving CA’s innovative expertise.